Related Experiment Videos
Lung transplantation in systemic sclerosis: A single center cohort study
Andreu Fernández-Codina1, Cristina Berastegui2, Iago Pinal-Fernández1
1Systemic Autoimmune Diseases Unit, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Passeig de la Vall d'Hebron 119-129, 08035 Barcelona, Spain.
Joint Bone Spine
|April 15, 2017
Summary
Lung transplantation (LT) is effective for systemic sclerosis (SSc) patients with advanced lung disease or pulmonary hypertension (PH). Survival and complications were similar to non-SSc patients, showing LT is a viable option.
Area of Science:
- Pulmonology
- Rheumatology
- Transplant Surgery
Background:
- Systemic sclerosis (SSc) can lead to severe interstitial lung disease (ILD) and pulmonary hypertension (PH).
- Lung transplantation (LT) is a potential treatment, but data on its efficacy and safety in SSc patients are limited.
Purpose of the Study:
- To evaluate the clinical features, complications, and survival rates of SSc patients undergoing LT.
- To compare the outcomes of LT in SSc patients with those of non-SSc patients.
Main Methods:
- A single-center cohort study included 15 SSc patients who underwent LT between 2005 and 2015.
- Eligibility followed standard criteria; gastroesophageal symptoms were not absolute contraindications.
- Outcomes were compared to a control group of non-SSc transplanted patients.
Main Results:
- The primary indication for LT was ILD, often with PH (4 cases).
- Acute cellular rejection and infections were the most common complications.
- Median survival was 2.4 years; survival and complication rates did not significantly differ from non-SSc patients.
Conclusions:
- LT is an effective treatment for advanced ILD and/or PH in SSc patients.
- Gastroesophageal reflux did not impede LT success in this cohort.
- LT outcomes in SSc patients are comparable to those in non-SSc patients.